ThromboGenics Plunges on Jetrea Sales Forecast: Brussels Mover
This article is for subscribers only.
ThromboGenics NV, the Belgian eye-drug developer, fell as much as 30 percent after forecasting that sales of its only approved product won’t increase in the second half of the year, missing analysts’ estimates.
ThromboGenics dropped to as low as 19.71 euros, the steepest intraday decline since it sold shares to the public in